Biotech · Private company
Xenikos
Track this companyFree. Adds Xenikos to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- RuxolitinibPhase 3 · Steroid-Refractory Acute Graft Versus Host DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- T-GuardPhase 3 · Steroid-Refractory Acute Graft Versus Host DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)PHASE3 · TERMINATED · started Jun 16, 2022ClinicalTrials.gov NCT04934670 · fetched Nov 12, 2026
- T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)PHASE3 · TERMINATED · started Nov 21, 2019ClinicalTrials.gov NCT04128319 · fetched Nov 12, 2026